最近鉴定慢性糖尿病并发症的治疗方法的努力导致发现了一系列新的高效和选择性的(2-芳基氨基甲酰基-苯氧基)乙酸醛糖还原酶抑制剂。化合物类别的特征是核心模板,该模板利用分子内氢键将药效基团的关键结构元件定位在构象中,从而促进了高结合亲和力。铅候选物,例如40,5-氟-2-(4-溴-2-氟-苄硫代氨基甲酰基)-苯氧基乙酸,抑制醛糖还原酶,IC(50)为30 nM,而对醛还原酶的活性低1100倍,是一种与活性醛解毒有关的酶。另外,实施例40在4天STZ诱导的糖尿病大鼠模型中以31mg / kg / d po的ED(50)降低了神经山梨糖醇水平。
thio-evodiamine (66c) showed excellent in vitro and in vivo antitumor efficacy with good tolerability and low toxicity. Antitumor mechanism and target profiling studies indicate that compound 66c is the first-in-class triple topoisomerase I/topoisomerase II/tubulin inhibitor. Overall, this study provided an effective strategy for natural product-based drug discovery.
The invention relates to a novel group of compounds of Formula (I) or a salt thereof:
wherein R
1
, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).
申请人:The Institute for Pharmaceutical Discovery LLC
公开号:US06420426B1
公开(公告)日:2002-07-16
Disclosed are substituted phenoxyacetic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds, alone or in combination with other therapeutic agents, and methods of treatment employing the compounds and pharmaceutical compositions, as well as methods for their synthesis.
Hypervalent‐iodine‐mediated oxidative coupling of the two aryl groups in either 2‐acylamino‐N‐phenyl‐benzamides or 2‐hydroxy‐N‐phenylbenzamides, with concomitant insertion of the ortho‐substituted N or O atom into the tether, has been described for the first time. This unusual metal‐free rearrangement reaction involves an oxidative C(sp2)C(sp2) aryl–aryl bond formation, cleavage of a C(sp2)C(O) bond